0000000000810184
AUTHOR
J. Neves
RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RECORD-2
ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…
New examples of Calabi-Yau threefolds and genus zero surfaces
We classify the subgroups of the automorphism group of the product of 4 projective lines admitting an invariant anticanonical smooth divisor on which the action is free. As a first application, we describe new examples of Calabi-Yau 3-folds with small Hodge numbers. In particular, the Picard number is 1 and the number of moduli is 5. Furthermore, the fundamental group is non-trivial. We also construct a new family of minimal surfaces of general type with geometric genus zero, K^2=3 and fundamental group of order 16. We show that this family dominates an irreducible component of dimension 4 of the moduli space of the surfaces of general type.